TransMedics Group, Inc. reported total revenue of $605.5 million for the year ended December 31, 2025, marking a 37.1% increase compared to the $441.5 million reported in 2024 and an 82.7% increase compared to the $241.6 million reported in 2023. Net product revenue reached $372.4 million, while service revenue amounted to $233.1 million. The company achieved a net income of $190.3 million for 2025, a significant increase from the $35.5 million net income in 2024. This financial performance reflects the company's growth in organ transplantation and related services.
The company's financial results were influenced by several operational developments. The National OCS Program (NOP) continued to drive adoption of the Organ Care System (OCS), with a focus on expanding its reach to both high-volume and smaller transplant centers. The acquisition of Summit Aviation, Inc. in August 2023, along with the subsequent purchase of 22 fixed-wing aircraft, enhanced the company's transplant logistics capabilities. These acquisitions and expansions were aimed at improving the efficiency and accessibility of organ procurement and delivery.
TransMedics is also investing in the development of its next-generation OCS technology. In 2025, the company introduced next-generation OCS improvements for lung and heart transplants through new clinical trials. These trials are intended to generate clinical evidence demonstrating the superiority of OCS over static cold storage methods. The company is also developing a Gen-3 multi-organ platform to improve OCS usability and incorporate new technology and automation.
Looking ahead, TransMedics plans to continue expanding its NOP, developing its next-generation OCS technology, and expanding internationally, particularly in key European countries. The company intends to construct research and development and manufacturing facilities in Italy to further expand its capabilities in Europe. These strategic initiatives are expected to drive future growth and solidify the OCS as the standard of care for solid organ transplantation.
About TransMedics Group, Inc.
TransMedics Group, Inc. develops and commercializes advanced organ preservation and transportation systems, primarily through its FDA-approved Organ Care System (OCS) platform for heart, lung, and liver transplants. The company offers innovative solutions for organ optimization, assessment, and logistics, increasing transplant access and improving outcomes. Its business model relies on device sales, disposable sets, and comprehensive logistics services, serving transplant centers worldwide.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.